Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azesal Skin Spray is a topical dermatological product manufactured by Gadin Biotech, an Indian generic pharmaceutical company. It is a combination formulation containing azelaic acid and salicylic acid, primarily indicated for the treatment of acne vulgaris and inflammatory skin conditions. Azelaic acid is a naturally occurring dicarboxylic acid that exhibits antimicrobial activity against *Cutibacterium acnes* and inhibits the synthesis of bacterial proteins; it also acts as a competitive inhibitor of tyrosinase, helping to reduce post-inflammatory hyperpigmentation. Salicylic acid is a beta-hydroxy acid that functions as a keratolytic agent, promoting the shedding of dead skin cells and unclogging pores. The spray delivery system is designed for convenient application to large body areas, such as the back and chest, which are frequently affected by acne.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azesal Skin Spray.